0.00Open0.20Pre Close0 Volume17 Open Interest23.00Strike Price0.00Turnover189.36%IV36.70%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier8DDays to Expiry0.20Extrinsic Value100Contract SizeAmericanOptions Type-0.0431Delta0.0090Gamma180.10Leverage Ratio-0.0540Theta-0.0004Rho-7.76Eff Leverage0.0049Vega
Exelixis Stock Discussion
Breakthrough: CABOMETYX Becomes First FDA-Approved Treatment for All Advanced NET Cancers
Exelixis Reveals Breakthrough Cancer Pipeline: 4 Novel Drugs Show Promise in Early Data
2.Based on the fourth-quarter and fiscal year 2024 financial report, Exelixis, Inc. demonstrated excellent performance. For the fourth quarter, the company reported net income of $139.9 millio...
Revolutionary Kidney Cancer Treatment Doubles Patient Survival: Final 5-Year Trial Results Revealed
No comment yet